06 October 2017 EMA/664954/2017 Inspections, Human Medicines Pharmacovigilance & Committees Division
Scientific recommendation on classification of advanced therapy medicinal products Article 17 – Regulation (EC) No 1394/2007
Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information. The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency. It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.
Brief description (or name when available) of the active substance(s) Allogeneic human glial-restricted precursors.
Brief description of the finished product Cryopreserved cells suspended in freezing solution.
Proposed indication Treatment of amyotrophic lateral sclerosis.
EMA/CAT conclusion The procedure was finalised on 14 September 2017 for the following recommendation. On the basis that the product:
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
consists of engineered cells or tissues, which have been subject to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration, repair or replacement are achieved;
•
is administered to human beings with a view to regenerating, repairing or replacing a human tissue,
the EMA/CAT considers that the product falls within the definition of a tissue engineered medicinal product as provided in Article 2(4) of Regulation (EC) 1394/2007.
Scientific recommendation on classification of advanced therapy medicinal products EMA/664954/2017
Allogeneic human glial-restricted precursors - European Medicines ...
Reproduction is authorised provided the source is acknowledged. 06 October 2017. EMA/664954/2017. Inspections, Human Medicines Pharmacovigilance & Committees Division. Scientific recommendation on classification of advanced therapy medicinal products. Article 17 â Regulation (EC) No 1394/2007. Disclaimer: ...
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. ⢠Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. ⢠Feraccru (ferr
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...
To receive each new issue of the newsletter, please click here RSS feeds, choose 'Human medicines · highlights newsletter' and then click on 'Subscribe to this ...
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to ...
For a list of RSS readers please refer to our RSS guide and follow the instructions .... WEB-RADR workshop report: mobile technologies and social media as.
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to ...
PCWP and HCPWP joint meeting - Sept 2016 - meeting documents. ⢠Workshop on identifying opportunities for 'big data' in medicines development and ...
Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss .... EMA's Business Continuity Plan for Brexit published.
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a ... Withdrawal of applications for new medicines .... fifth annual regulatory conference on optimising the development of advanced therapies to.
Key information for patients, consumers and healthcare professionals. Published monthly by the European Medicines Agency. An agency of the European Union. HUMAN MEDICINES. HIGHLIGHTS. Issue 107. February 2018. This newsletter is addressed primarily t
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to ...
For a list of RSS readers please refer to our RSS guide and follow the instructions .... granted a conditional marketing authorisation on the basis of less complete ...
monitoring. 5. Guidelines. 5. Scientific .... Updated list of medicinal products under additional monitoring. Other information. Guidelines. Guidelines open for consultation ... CHMP -applications for new human medicines under evaluation: April 2016
HUMAN MEDICINES. HIGHLIGHTS. Issue 105. December 2017. This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use
Jan 29, 2018 - professionals. It provides a summary of key information relating to medicines for human use published ... Information is selected based on recommendations from consulted patients, consumers and healthcare professionals, and .... 30 Chu
desktop news reader. For a list of RSS readers please .... CHMP -applications for new human medicines under evaluation: April 2016. ⢠2016 work plan for the ...
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...
May 3, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).